GLB1L2 Inhibitors
GLB1L2 inhibitors encompass a diverse array of chemical compounds that interact with distinct signaling pathways within the cell, ultimately leading to the reduced activity of GLB1L2. Lithium Chloride, for example, exerts an indirect effect on GLB1L2 by targeting the GSK-3 signaling pathway, which is known to influence the stability of various proteins within the cell, including potentially GLB1L2. Rapamycin's interaction with FKBP12 affects the mTORC1 pathway, a central regulator of cellular growth and protein synthesis, suggesting a mechanism by which GLB1L2 expression could be downregulated as part of the broader cellular response to stress and nutrient deprivation. Similarly, compounds like LY294002 and Omipalisib target the PI3K/AKT/mTOR pathway, a critical signaling cascade for cell survival and growth, indicating that GLB1L2 expression could be modulated as a part of the comprehensive response to changes in cell metabolism and growth signals. Inhibitors such as SB203580, PD98059, SP600125, PP2, U0126, Dasatinib, Gefitinib, and Sorafenib interfere with various kinases involved in cell signaling, which may lead to altered expression or activity of GLB1L2 due to their roles in cell cycle regulation, apoptosis, and response to cellular stress. Each of these inhibitors, by modulating different pathways, contributes to a multifaceted approach to the potential downregulation of GLB1L2, reflecting the complexity of cellular signaling networks and their impact on gene expression
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride indirectly inhibits GLB1L2 by modulating glycogen synthase kinase 3 (GSK-3) activity. Inhibition of GSK-3 leads to the stabilization of β-catenin, which can then enter the nucleus and affect the expression of genes that contribute to the downregulation of GLB1L2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTORC1, leading to dephosphorylation of downstream effectors such as S6K1. Reduced activity of S6K1 correlates with decreased protein synthesis and can result in lowered expression of GLB1L2 as part of a broader response to inhibited cell growth and proliferation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that prevents the phosphorylation of downstream targets involved in inflammatory responses and stress signals. Inhibition of this pathway can decrease the expression of stress-induced proteins, which may include GLB1L2 as a stress-responsive protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, leading to reduced AKT phosphorylation. Without active AKT, downstream signaling pathways involved in cell survival and protein translation are downregulated. This can contribute to reduced expression and activity of survival proteins including GLB1L2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which prevents the activation of ERK1/2. Inhibition of ERK signaling can lead to decreased expression of genes under the control of this pathway, potentially including GLB1L2 if it is regulated as part of the cellular response to ERK-mediated signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. By inhibiting JNK, the compound suppresses the activity of transcription factors regulated by JNK, such as c-Jun. This can lead to reduced transcription of genes that are under the control of these transcription factors, including possibly GLB1L2 if it is within this regulatory network. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor which leads to reduced cell proliferation and survival signaling. Src kinases can regulate a variety of cellular processes including those that may govern the stability or expression of GLB1L2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL kinase inhibitor that also inhibits Src family kinases. By targeting these kinases, dasatinib disrupts multiple signaling cascades that contribute to cell proliferation and survival, potentially affecting the expression levels of proteins such as GLB1L2. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor which may decrease the expression of GLB1L2 by inhibiting EGFR tyrosine kinase activity, leading to reduced downstream signaling through pathways like MAPK and PI3K that can regulate gene expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor that can decrease signaling through the MAPK/ERK pathway, potentially leading to the downregulation of genes that are upregulated in response to this pathway's activity, which may include GLB1L2. | ||||||